Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Schwartz

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Molecular Therapy. Methods & Clinical Development|September 12, 2022
Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type ICristina Mesa-Núñez, Carlos Damián, María Fernández-García, et al.
The New England Journal of Medicine|November 18, 2024
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon DiseaseBarry Greenberg, Matthew Taylor, Eric Adler, et al.
Journal of Neuropathology and Experimental Neurology|February 14, 2026
Dysembryoplastic neuroepithelial tumor: Malignant transformation following radiationYi Zhu, Cristiane M Ida, Jonathan D Schwartz, et al.
Frontiers in Pediatrics|August 27, 2025
Case Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemiaJosune Zubicaray, June Iriondo, Elena Sebastián, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanomaRichard D Carvajal, Michael K Wong, John A Thompson, et al.
American Journal of Hematology|January 6, 2022
Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKDJonathan D Schwartz, Wilma Barcellini, Rachel F Grace, et al.
Pediatric Blood & Cancer|October 19, 2023
Busulfan and subsequent malignancy: An evidence-based risk assessmentJanel R Long-Boyle, Donald B Kohn, Ami J Shah, et al.
Cancer|March 1, 2014
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapyJorge A Garcia, Gary R Hudes, Toni K Choueiri, et al.
Cancer Investigation|December 8, 2004
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neuHoward Safran, David Iannitti, Ramesh Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinomaAbby B Siegel, Emil I Cohen, Allyson Ocean, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Molecular Therapy. Methods & Clinical Development|September 12, 2022
Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type ICristina Mesa-Núñez, Carlos Damián, María Fernández-García, et al.
The New England Journal of Medicine|November 18, 2024
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon DiseaseBarry Greenberg, Matthew Taylor, Eric Adler, et al.
Journal of Neuropathology and Experimental Neurology|February 14, 2026
Dysembryoplastic neuroepithelial tumor: Malignant transformation following radiationYi Zhu, Cristiane M Ida, Jonathan D Schwartz, et al.
Frontiers in Pediatrics|August 27, 2025
Case Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemiaJosune Zubicaray, June Iriondo, Elena Sebastián, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanomaRichard D Carvajal, Michael K Wong, John A Thompson, et al.
American Journal of Hematology|January 6, 2022
Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKDJonathan D Schwartz, Wilma Barcellini, Rachel F Grace, et al.
Pediatric Blood & Cancer|October 19, 2023
Busulfan and subsequent malignancy: An evidence-based risk assessmentJanel R Long-Boyle, Donald B Kohn, Ami J Shah, et al.
Cancer|March 1, 2014
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapyJorge A Garcia, Gary R Hudes, Toni K Choueiri, et al.
Cancer Investigation|December 8, 2004
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neuHoward Safran, David Iannitti, Ramesh Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinomaAbby B Siegel, Emil I Cohen, Allyson Ocean, et al.
Pageof 6